Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Product development report: CPRIT seed conversion rising; March Biosciences credits CPRIT, accelerator and local investors
Summary
CPRIT product development staff reported a strong preliminary‑to‑full application conversion rate and discussed supplemental awards. March Biosciences, a Houston cell‑therapy startup funded through local accelerator and CPRIT awards, presented early clinical progress and said CPRIT funding was a pivotal bridge to Series A.
CPRIT’s product development team reported Aug. 20 that the office completed preliminary application reviews for cycle 26.1, invited 24 applicants to submit full applications and received 23 full submissions. Staff outlined panel scoring distributions and conversion rates, and product development advisory committee (PDAC) members urged continued attention to portfolio diversification and follow‑on funding for strong grantees.
Product development staff said therapeutics still dominate applications but highlighted that seed and device/diagnostic applications had higher panel conversion rates to full…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
